University of Pennsylvania Medical Center is a medical institution in Philadelphia identified in the book as the institutional affiliation of David Roth, one of the authors of the chapter “Kidney Transplantation in the Patient with Hepatitis C Virus Infection.” The supplied evidence does not describe a particular ward, procedure, or patient encounter there; instead, it places the center within the clinical and research network through which HCV-related kidney disease and transplantation are examined.

Institutional Identity and Setting

University of Pennsylvania Medical Center is listed alongside the Nephrology Department at Hospital 12 de Octubre in Madrid and the Division of Nephrology and Hypertension at the University of Miami Miller School of Medicine. This author-affiliation listing situates the center within an international nephrology collaboration rather than presenting it as an isolated local facility. Its associated city is Philadelphia, and its documented connection in the text is specifically to David Roth’s contribution to the transplantation chapter.

Clinical Questions in the Surrounding Evidence

The chapter’s subject is the management of kidney transplant candidates and recipients with HCV infection. The surrounding evidence emphasizes that transplant candidates require screening for anti-HCV antibodies and, where appropriate, active viremia through nucleic acid testing. Active chronic infection is distinguished from resolved infection by the presence of HCV RNA in serum, while evaluation of hepatic injury may require liver biopsy because noninvasive tests have not been shown to provide equivalent accuracy in every transplant candidate.

The institutional context also encompasses the difficult staging decisions faced by HCV-infected patients with end-stage renal disease. Patients with established or decompensated cirrhosis may require referral for simultaneous liver-kidney transplantation, whereas patients remaining on a kidney waiting list need continuing surveillance for progression of liver disease. The evidence notes that waiting times in some areas of the United States approach five to seven years, making repeated assessment a practical component of transplant eligibility rather than a one-time screening exercise.

Research and Policy Context

University of Pennsylvania Medical Center appears within a broader evidence-based discussion shaped by transplant guidelines, dialysis studies, and registry data. Patients who test positive for HCV RNA while awaiting transplantation may be placed on hold and referred to a hepatologist for evaluation and possible antiviral treatment. Those who have achieved a sustained virological response require at least annual nucleic acid testing to confirm that the response remains durable, while patients who remain viremic require periodic reassessment of hepatic progression.

The surrounding literature also addresses the allocation of HCV-positive donor kidneys. Organ shortage has produced large disparities between the number of people awaiting transplantation and the number of procedures performed, while kidneys from HCV-positive donors have often been discarded because suitable recipients were not identified or because centers differed in their willingness to use such organs. The evidence reports that HCV-positive kidneys were 2.60 times more likely to be discarded than HCV-negative kidneys and considers transplantation into HCV-positive recipients as one possible way to reduce waiting time when antiviral treatment is unsuitable, unsuccessful, refused, or unaffordable.

Significance in the Book

The center’s narrative significance is institutional rather than scenic. It represents the specialized medical infrastructure through which HCV status is classified, liver injury is staged, treatment toxicity is weighed, and access to kidney transplantation is organized. The evidence links these decisions to concrete clinical tensions: interferon therapy after transplantation carries an increased risk of renal allograft rejection; antiviral treatment before transplantation can be prolonged and toxic; and some HCV-infected patients may nevertheless fare better with transplantation than by remaining on dialysis.

By naming University of Pennsylvania Medical Center among the affiliations behind this discussion, the book places the center within an international production of transplant knowledge connecting Philadelphia, Madrid, and Miami. Its documented role is therefore that of a clinical-academic node in the management of HCV and kidney transplantation, not a separately narrated location with its own described events.